Data suggest high dose used in phase 3 trial is most effective
Generic was developed with India’s Natco.
Initiative aims to find new immunotherapies.
Swiss pharma looks to offload struggling division.
Drug successful in late stage trial for giant cell arteritis
But senators call for investigation into EpiPen schools contracts.
Swiss pharma looking to combine immunotherapy with already marketed drugs.
Cancer immunotherapy approved in second line.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer